10-May-2024
TipRanks (Fri, 10-May 6:45 AM ET)
Adverum Biotechnologies (ADVM) Receives a New Rating from RBC Capital
TipRanks (Fri, 10-May 6:39 AM ET)
Adverum Biotechnologies GAAP EPS of -$1.50
Seeking Alpha News (Thu, 9-May 5:34 PM ET)
Globe Newswire (Thu, 9-May 4:05 PM ET)
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
Globe Newswire (Fri, 3-May 8:00 AM ET)
Globe Newswire (Thu, 25-Apr 4:05 PM ET)
Globe Newswire (Mon, 18-Mar 4:05 PM ET)
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
Globe Newswire (Wed, 28-Feb 4:05 PM ET)
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Adverum Biotechnologies trades on the NASDAQ stock market under the symbol ADVM.
As of May 10, 2024, ADVM stock price declined to $9.30 with 253,550 million shares trading.
ADVM has a beta of 1.03, meaning it tends to be more sensitive to market movements. ADVM has a correlation of 0.02 to the broad based SPY ETF.
ADVM has a market cap of $193.02 million. This is considered a Micro Cap stock.
In the last 3 years, ADVM stock traded as high as $40.10 and as low as $5.31.
The top ETF exchange traded funds that ADVM belongs to (by Net Assets): VTI, VXF, DFAC, ITOT, FESM.
ADVM has underperformed the market in the last year with a price return of +9.5% while the SPY ETF gained +27.8%. ADVM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -46.2% and +1.2%, respectively, while the SPY returned +4.2% and +2.5%, respectively.
ADVM support price is $9.12 and resistance is $10.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADVM stock will trade within this expected range on the day.